Stock Financial Ratios, Dividends, Split History

LEN.B / Lennar Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price44.09
Volume71,000.00
Market Cap ($M)9,016.73
Book Value ($M)7,872.32
Book Value / Share38.60
Price / Book1.15
NCAV ($M)-10,758.90
NCAV / Share-45.37
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 237,156,000
Common Shares Outstanding2 36,007,774
Common Shares Outstanding 203,952,285
Weighted Average Number Of Shares Outstanding Basic 237,155,000
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.10
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Assets18,745.03
Liabilities10,758.90
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues12,646,365,000.00
Operating Income1,475.50
Net Income771.75
Earnings Per Share Basic3.38
Earnings Per Share Diluted3.38
Cash Flow Statement (mra) ($M)
Cash From Operations996.86
Cash from Investing-869.82
Cash from Financing-869.82
Identifiers and Descriptors
CUSIP526057302
Central Index Key (CIK)920760
Related CUSIPS
526057902 526057952

Split History

Stock splits are used by Lennar Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

9h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Related News Stories

Here's Why You Should Buy TRI Pointe (TPH) Stock Right Now

2018-07-12 zacks
TRI Pointe Group, Inc.’s (TPH - Free Report) shares have been riding high of late, gaining 24.7% over the past year compared with the industry’s 3.9% growth. Indeed, the overall outlook for the U.S. housing industry remains positive, with a healthy economy and strong job market aiding the demand side of the equation. However, the limited supply of homes for sale, rising rates and higher material prices have raised concerns among investors regarding certain U. (1-0)

5 Stocks With Domestic Focus to Evade Trade War Fears

2018-07-11 zacks
On Jul 10, President Donald Trump escalated fears of a trade war further by threatening to impose 10% tariffs on an additional $200 billion of Chinese goods. The move comes within days of the two countries imposing tit-for-tat tariffs on goods worth $34 billion. This once again made investors jittery, leading to huge selloffs on Tuesday. (2-0)

Lennar Corporation (LEN): An Off-the-Radar Potential Winner

2018-07-09 zacks
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach. So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision. One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Lennar Corporation (LEN - Free Report) .

Mortgage Rates Dip to 3-Month Low: Top 4 Housing Picks

2018-07-06 zacks
After increasing for most of the spring, mortgage rates dipped for the week ending Jul 5 to the lowest level since mid-April, renewing hope for would-be homebuyers. Notably, the cost of borrowing fell in five of the past six weeks. According to Freddie Mac, the average interest rate on a 30-year fixed-rate mortgage was 4.52% in the week ending Jul 5 compared with 4.55% in the week earlier. The 15-year fixed-rate mortgage averaged 3. (17-0)

Acuity Brands' (AYI) Q3 Earnings, Sales Beat Estimates

2018-07-03 zacks
Acuity Brands, Inc. (AYI - Free Report) reported third-quarter fiscal 2018 adjusted earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.17 by 9.2%. Also, earnings increased 10.2% on a year-over-year basis. The upside can be attributed to increase in net sales driven by greater shipments of Atrius-based luminaires along with products for infrastructure and utility projects. Sales Net sales during the quarter were $944 million, beating the Zacks Consensus Estimate of $906. (6-0)

CUSIP: 526057302